T cell depletion (TCD) of marrow is a proven method of graft-versus-host disease (GVHD) prophylaxis in allogeneic bone marrow transplantation (BMT). Nonetheless, TCD is associated with an increased risk of developing post transplant lymphoproliferative disorder (PTLD). Between 1986 and 1998, 241 pediatric patients at the University of Iowa underwent BMT using ex vivo TCD of marrow from mismatched related or matched unrelated donors. Additional GVHD prophylaxis included antithymocyte globulin (ATG) or anti lymphocyte globulin (ALG) post transplant (in vivo TCD). A total of 30 cases of PTLD were identified based upon a combination of clinical, histological, and immunological features. Nearly all cases occurred within 3 months post BMT. A statistically significant increase in PTLD incidence was noted for patients treated with ATG vs ALG (33 vs 9%). While grade I-II acute GVHD was more common in patients receiving ATG vs ALG, no difference in grade III-IV GVHD or overall survival was noted between the two groups. Assessment of immune recovery at various times post BMT revealed significantly fewer T cells in the ATG-treated group, suggesting the deleterious effect of ATG may be due to excessive depletion of donor-derived Epstein-Barr virus-specific cytotoxic T cells. Thus, caution should be exercised in the use of anti-T-cell antibody therapy for additional GVHD prophylaxis in the setting of TCD BMT.
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1,2 EBV-specific cytotoxic effector T cells are believed to control proliferation of EBV-infected B cells, 3 which in pediatric transplant patients are often of donor origin. 4 PTLD is rarely seen in bone marrow transplantation (BMT) recipients receiving marrow from matched sibling donors, but its incidence in patients receiving marrow from mismatched related or matched unrelated donors ranges from 8 to 24%. [5] [6] [7] [8] Since only 25 -30% of BMT candidates have HLA-identical sibling donors, the use of alternative donors has become widespread, 9,10 thus placing more patients at risk for PTLD.
Ex vivo T-cell depletion (TCD) of bone marrow is commonly employed as graft-versus-host disease (GVHD) prophylaxis, particularly in patients receiving alternative donor transplants. In this patient population, TCD is associated with less severe acute GVHD, although the incidence of graft failure and relapse is increased. [10] [11] [12] Ex vivo TCD is rarely employed in pediatric patients receiving matched sibling donor transplants, although the incidence of PTLD in adults receiving TCD marrow with Campath from matched sibling donors was only 1.3%. 13 Previous analyses have shown that ex vivo TCD, in vivo anti-T-cell antibody therapy, and HLA donor/recipient incompatibility are risk factors for the development of PTLD. 5, 6, 14, 15 While depletion of B cells by ex vivo treatment of the marrow with anti-B-cell antibodies may decrease the risk of PLTD, a protective effect of in vivo B-cell-depleting therapies following BMT has not been well established. [15] [16] [17] In vivo depletion of T cells with polyclonal antilymphocyte globulin (ALG) and antithymocyte globulin (ATG) has been utilized for many years, both as treatment and prevention of acute GVHD. Of note, a study in solid organ transplant recipients suggested a more thorough depletion of T lymphocytes in patients receiving ATG. 18 Among 215 pediatric patients who underwent ex vivo TCD BMT from alternative donors at The University of Iowa, 30 (14%) developed PTLD with a median follow-up of 8 years. A retrospective analysis was carried out to assess risk factors for this condition. The use of ATG, relative to ALG, significantly increased the likelihood of developing PTLD. In an attempt to understand the mechanisms behind this finding, we examined lymphocyte immunophenotyping studies early post BMT. Importantly, we found significantly lower T lymphocyte numbers in the peripheral blood early post BMT in ATG-treated vs ALGtreated patients. These novel findings are consistent with other studies and suggest that lymphocyte-depleting strategies for GVHD prophylaxis could be improved by preventing excessive loss of lymphocytes that may be providing specific immunity to EBV.
Materials and methods

Patient population
From June 1986 to December 1998, 241 pediatric patients at the University of Iowa Hospitals and Clinics underwent allogeneic BMT with T-cell-depleted grafts from alternative donors. Demographic data are presented in Table 1 . Of these patients, 215 engrafted and lived 421 days post BMT; thus, they were evaluable and considered at risk for PTLD. High-risk patients were defined as patients transplanted in relapse or with residual disease at the time of transplant. All patients were advised of procedure risks and signed informed consent approved by the committee on the use of human subjects and research at the University of Iowa. Patients were also assigned unique patient numbers (UPN).
Donor type
BMT recipients received grafts from mismatched family member donors (161) and matched unrelated donors (54). HLA testing (A, B, and Dr) was performed exclusively by serological methods until 1991, thereafter Dr identity was confirmed by DNA typing. Of the 161 mismatched marrows from related donors, 79 were haploidentical (3/6), 49 were Dr-identical (14 were 5/6 matched, 35 were 4/6) and 33 were either matched at 4/6 (29) or 5/6 (4) but Dr mismatched. Of the 54 marrows from unrelated donors, 25 were matched completely (6/6) while 27 were 5/6 and two were 4/6 matched.
Preparative therapy
The majority of patients (175/215) received a standard conditioning regimen of intravenous (i.v.) etoposide 250-750 mg/m 2 /day (days -9 and -8), cytosine arabinoside (Ara-C) 3 gm/m 2 /dose i.v. twice daily (days -7, À6, and -5), cyclophosphamide 45 mg/kg/day i.v. (days -5 and -4), intrathecal (i.t.) Ara-C 70 mg (days -10 and À4) and total body irradiation at 1200 cGy with lung shielding after 900 cGy in six fractions (days -3, À2, and À1). A total of 11 patients received the standard conditioning regimen minus etoposide. A total of 16 patients received busulfan 1 mg/kg p.o. every 6 h Â 16 doses (days -8, À7, À6, and À5), cyclophosphamide 45 mg/kg i.v. Â 2 days (À3 and À2), Ara-C 3 g/m 2 i.v. every 12 h Â 6 doses (days -4, À3, À2), and i.t. Ara-C 70 mg Â 2 doses (days -9, À1). In all, 13 patients received other myeloablative regimens that did not contain radiation.
Marrow preparation
Ex vivo TCD of bone marrow was performed as previously described. 19 Prior to February 1995, ex vivo TCD was accomplished using CT-2 (murine IgM anti-human CD2 antibody) plus baby rabbit serum as a source of complement. Since February 1995, OKT3 (monoclonal antihuman CD3 antibody) was substituted for CT-2. Both antibody treatments (CT-2 and OKT3) resulted in a twothree log depletion of T cells from the graft. While similar numbers of CD3+ T cells were infused into patients receiving TCD grafts, extensive immunophenotyping was not performed and thus it is unknown whether there were differences in T-cell subpopulations in grafts depleted with CT-2 vs OKT3. 
Graft vs host disease prophylaxis and supportive care
GVHD prophylaxis included ex vivo TCD (as described above) as well as in vivo TCD with either ALG or ATG. ALG (Swiss Serum and Vaccine Institute, Berne, Switzerland) was produced by fractionation of plasma isolated from horses immunized with human thoracic duct lymphocytes. By virtue of both T and B lymphocytes being contained in the thoracic duct, ALG has high titers to B-cell antigens. ATG (ATGAM, Upjohn, MI, USA) was similarly produced from horses immunized with human thymocytes and thymic tissue. Owing to commercial availability, ATG replaced ALG in November 1993. Both agents were administered at 20 mg/kg i.v. every other day for eight doses starting the day prior to BMT. ATG-and ALG-treated patients received identical post transplant GVHD prophylaxis consisting of methylprednisolone (1 mg/kg/day alternating with 2 mg/kg/day) for 1 month post BMT followed by slow taper. All patients were hospitalized in single rooms within the HEPA-filtered Pediatric Bone Marrow Transplant Unit and received prophylactic antimicrobials, as previously described. 20 
Diagnosis of PTLD
All 30 patients who developed PTLD had clinical features of this disease, including fever, lymphadenopathy, and hepatosplenomegaly. In 23 cases (77%), tissue biopsies allowed histopathologic confirmation, using World Health Organization (WHO) Classification of lymphoid neoplasms. 21 In seven patients without biopsy material, the diagnosis of PTLD was established by immunopathologic or molecular assays of blood and serum that included: Southern blot analysis for EBV DNA terminal repeat structures 22 (UPN 10, 15, 17, 23, 26) , EBV RNA in situ hybridization 23 (UPN 25), and serum immunofixation electrophoresis 24 with detection of monoclonal Ig heavy and/or light chains (UPN 4, 10, 15, 23).
Immunophenotyping
Lymphocyte immunophenotyping was routinely performed at monthly intervals early post BMT for most patients. For this analysis, flow cytometry data were only included for patients without evidence of disease relapse, graft rejection, or PTLD, as these specific conditions could independently affect lymphocyte immunophenotype. The absolute number of B (CD20+), T (CD3+, CD4+, and CD8+), and NK (CD3-and CD16/56+) cells were compared between ALG-and ATG-treated patients. Immunophenotyping analyses performed post BMT were as follows: 1 month ALG (n ¼ 29) and ATG (n ¼ 25); at two months ALG (n ¼ 23) and ATG (n ¼ 14); and at 3 months ALG (n ¼ 21) and ATG (n ¼ 6). Immunophenotyping was performed as described previously. 20 
Outcome criteria
The primary outcome of this study was time until onset of PTLD, with all patients receiving at least 4 years follow-up post BMT. Of note, no patient developed PTLD more than 1 year post BMT. Additionally, graft failure/rejection, acute and chronic GVHD, and disease relapse were compared in patients treated with ALG and ATG at 2 years post BMT. Patients surviving 21 days post BMT were considered 'at risk' for graft failure/rejection using published criteria. 25 Acute GVHD was clinically defined as mild (grade I-II) or severe (grade III-IV) using published criteria, and patients considered 'at risk' needed to have survived 21 days post BMT with laboratory evidence of engraftment. 26 Chronic GVHD was defined by clinical criteria and did not require biopsy. Patients 'at risk' for chronic GVHD had to survive greater than 90 days post BMT with engraftment. 27 Disease relapse was defined as hematologic or clinical recurrence of primary disease at any site. Patients in the relapse analysis included those transplanted for ALL, ANLL, CML, solid tumors, histiocytosis X, or myelodysplastic syndrome. Overall survival (OS) at 5 years was also compared between patients treated with ALG and ATG.
Study and statistical analysis
Cox proportional hazards regression models 28 were used to identify factors associated with time until onset of PTLD censored at 1 year post BMT for all 'at-risk' patients and for all 'at-risk' patients in remission at the time of BMT. Possible confounding factors analyzed by univariate and multivariate methods were age (48 vs 0-8 years; breakpoint determined by the median), diagnosis (ALL, AML, CML, other), conditioning regimen (radiation plus chemo vs chemo alone), donor type (haploidentical, Dr-identical, unrelated), and GVHD prophylaxis (ALG/CT-2, ATG/ CT-2, ATG/OKT3). Multivariate analysis was performed by the backward stepwise model building technique. 29 In this analysis, the factor with the highest P-value is removed at each step until a point is reached when all factors left had Po0.05. These remaining factors form the final multivariate model. Cox proportional hazards regression was used to assess OS. Patients were censored at the date of last follow-up or at 5 years, whichever occurred first. The w 2 test was utilized to compare the effect of the type of in vivo GVHD prophylaxis on the outcomes of graft rejection/ failure, disease relapse (only for patients transplanted in remission), acute and chronic GVHD. Analysis of post transplant immunophenotyping was by the Wilcoxon ranksum test.
Results
PTLD risk factor analysis
A number of risk factors have previously been shown to be associated with PTLD. In our analysis, we assessed the following risk factors: age, gender, primary diagnosis, type of GVHD prophylaxis, donor type, and conditioning regimen. None of the patients who received two transplants developed PTLD. The annual incidence of PTLD was fairly consistent in the first 7 years of this study, ranging from 7 to 13% (Figure 1 ). However, a sharp increase in PTLD occurred in 1993, and thereafter till 1998 the yearly incidence ranged from 27 to 38%. Both univariate and multivariate analyses confirmed ATG to be the only significant risk factor (hazard ratio ¼ 3.57, P ¼ 0.001) for PTLD development (Table 2 ). During the time period when ALG was used exclusively, 9% (16/172) of children receiving TCD BMT from alternative donors developed PTLD. Following the change to ATG in 1993, 33% (14/43) of 'at-risk' patients developed this condition. There was no significant difference in the incidence of PTLD in ATGtreated patients whose grafts were depleted of T cells ex vivo with CT-2 (7/20) vs OKT3 (7/23). Also, no significant differences were noted in patients receiving TCD BMT from Dr-identical, haploidentical, or unrelated donors. The risk factors of recipient age, initial diagnosis, presence of total body irradiation in the conditioning regimen, GVHD, and additional immunosuppressive therapy were not significant for development of PTLD. In a repeat analysis excluding 'high-risk' patients (ie those with residual disease at the time of transplant), ATG was again the only significant risk factor for PTLD development (data not shown).
Correlation of immunophenotype with PTLD
During the course of this study, many patients had peripheral blood immunophenotyping performed at monthly intervals, as previously reported. 20 In this current study, quantitative recovery of lymphocyte populations was determined for the first 3 months post transplant (risk period for PTLD development), and data are expressed as mean absolute lymphocyte count per mm 3 7s.e.m. (Table 3 ). Since B cells are presumed to be the 'reservoir' for EBV, we first examined B-cell recovery in ALG-and ATG-treated patients. Very few B cells were observed at 1 month post BMT. At 2 months post BMT, ALG-treated patients had lower B-cell numbers compared to ATGtreated patients, although this difference was not statistically significant. Comparing B-cell recovery in a matched cohort of patients receiving non-TCD transplants from matched sibling donors, a marked difference was noted, with B-cell counts ranging from 250 to 500 at 2 and 3 months post transplant (data not shown). Given the importance of cellular immunity in controlling PTLD, EBV, and viral infections, we next examined different T-cell compartments in ALG-vs ATG-treated patients. Of note, the total number of CD3+ T cells was significantly lower in ATG-compared to ALG-treated patients at 1 month post BMT (P ¼ 0.005). Similarly, at 2 and 3 months post BMT, CD3+ T-cell counts were lower in ATG-compared to ALG-treated patients, although these differences were not statistically significant. Examination of T-cell subsets revealed CD4+ T-cell counts to be significantly lower in ATG-treated patients at 1 and 3 months post BMT relative to ALG-treated patient during the same time period (Po0.05). We were unable to detect a significant difference between the absolute numbers of CD8+ T cells in the ALG-vs the ATG-treated group at 1, 2, or 3 months post BMT. However, we believe this was due to the fact that CD8 counts were artifactually elevated in both groups due 
, and decreased immunosuppression (n ¼ 17). During the later time period, following publication of several reports demonstrating the benefit of cellular immunotherapy for this condition, nine patients also received donor lymphocyte (DLI) infusions. While multiple treatment modalities were used for all PTLD patients, there appeared to be an increased benefit for those given DLI. Of the 10 patients who responded to therapy, five had received DLI, and three of these survived greater than 2 years. The outcomes of graft failure/rejection, relapse of primary disease, and GVHD (acute and chronic) at 2 years post BMT were compared in 'at-risk' patients who received either ALG or ATG. An increased incidence of graft failure was noted in patients treated with ALG (14.4%) compared to those treated with ATG (6.5%), although this difference was not statistically significant. The incidence of grade I-II acute GVHD was significantly higher in ATG-vs ALGtreated patients (58.1 vs 33.7%, Po0.01). Interestingly, while previous studies have shown a lower incidence of disease relapse in patients achieving grade I-II acute GVHD, this was not observed in our current analysis. The incidence of grade III-IV acute GVHD was similar in ATG-vs ALG-treated patients, although a higher incidence was found in patients who developed PTLD relative to those who did not develop PTLD (19 vs 7%). The incidence of disease relapse was 27% for both ATG-and ALGtreated patients (data not shown). Survival analyses were performed for the entire cohort of pediatric BMT patients receiving marrow from matched unrelated or mismatched related donors, with a 5-year OS rate of 22% (data not shown). Eliminating 'high-risk' patients (those transplanted in relapse) from this analysis, 5-year OS rate increased to 33%. Analyzing standard risk and high-risk relapsed patients separately, no difference in survival was noted for patients treated with ALG compared to ATG. However, as per our previous report, 30 high-risk relapsed patients were at significant risk of dying (hazard ratio ¼ 3.05, P ¼ o0.0001) compared to standard risk patients.
Discussion
PTLD is an often-fatal complication of allogeneic BMT, occurring with increased frequency in patients receiving T-cell-depleted transplants. From 1986 to 1998 pediatric patients at the University of Iowa undergoing allogeneic BMT using matched unrelated or mismatched family member donors received T-cell-depleted grafts. For additional GVHD prophylaxis, patients also received in vivo anti-T-cell antibody therapy post transplant with either ATG or ALG. During the first 7 years of this study (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) , 16/172 (9.3%) pediatric patients developed PTLD, an incidence similar to that reported by other transplant centers. 5, 6, 13, 14 In 1993, due to the lack of commercial availability of ALG, ATG was used for in vivo TCD. Following this change, 14/43 (33%) patients from a similar 'at-risk' population developed PTLD, a disease incidence significantly higher than previously observed at our center. During this same time period, other BMT centers were not reporting higher PTLD rates.
Several prior studies have analyzed risk factors for PTLD in BMT patients. Our current retrospective analysis clearly shows ATG, relative to ALG, to be a risk factor for PTLD development. While retrospective analyses are at times limiting, a number of other published reports have also hinted at the danger of excess immunosuppression with anti-T-cell antibody therapy in the transplant setting. In a multivariate analysis of 11 462 adult and 6552 pediatric patients undergoing allogeneic BMT from 235 centers, 5 the relative risk (rr) of developing PTLD was increased in patients receiving ex vivo TCD of marrow (rr ¼ 12.7) and anti-T-cell antibody therapy for prophylaxis or treatment of acute GVHD (rr ¼ 6.4). Similarly, in solid organ transplantation, anti-T-cell antibody (OKT3) therapy as part of an antirejection regimen predisposed patients to PTLD, 31, 32 and those receiving sequential therapy with OKT3 + ALG had the greatest risk. 33 Interestingly, while ATG (relative to ALG) was a significant risk factor for PTLD in our patient population, there was no difference in OS. In fact, both methods of in vivo TCD were associated with a relatively low incidence of acute GVHD, and overall 50% of patients failed to develop any degree of acute or chronic GVHD. Of note, while the type of T-cell antibodies used for ex vivo TCD of bone marrow did not affect outcome or PTLD development in our study, ex vivo TCD with narrow specificity antibodies (ie OKT3) has been reported to be associated with less transplant-related mortality and more GVHD than broad-spectrum antibodies (Campath-1, elutriation, and lectins/sheep RBC). 12 A number of reports have shown T-cell depletion of bone marrow to be associated with delays in T-cell immune reconstitution post BMT. Combining ex vivo TCD of marrow (CT-2) with in vivo anti-T-cell antibody therapy (ALG) post BMT prophylaxis, we previously reported a 9-12 months delay for CD3+ T cells to increase above 500/ mm 3 and CD4+ T cells to increase above 200/mm 3 . 20 In our current analysis, ATG was associated with lower CD3+ and CD4+ T-cell counts compared to ALG in the first 3 months post BMT. The role of T cells in preventing PTLD post BMT was reported in a study by Gerritsen, where pediatric BMT patients with o50/mm 3 CD3+
T cells at 1 month post BMT and/or o100/mm 3 CD3+ T cells at 2 months post BMT were found to be at increased risk for PTLD. 6 In addition to the qualitative defects in T-cell recovery during the first 3 months post TCD marrow transplantation, we would also anticipate T-cell function to be quite poor in these patients, as previously described. 20 Other previously reported PTLD risk factors, including use of haploidentical bone marrow donors and occurrence of severe (grade III-IV) acute GVHD, 5, 13 were not independently associated with an increased incidence of PTLD in our multivariate analyses. While complete depletion of T cells from bone marrow increases the risk of PTLD, methods that concomitantly remove B cells (ie anti-B-cell antibodies, counterflow elutriation, and CD34 positive selection) may have a protective effect. [15] [16] [17] In fact, ALG contains significant anti-B-cell antibody titers 34 and has an antiproliferative effect on B cells in vitro. 35 Thus, it is possible that ALG could have had a protective effect in our study by removing EBV-infected B cells, although immunophenotyping data did not demonstrate statistically significant differences in B-cell recovery early post BMT for ALG-vs ATG-treated patients. Finally, it is feasible that differences in immune recovery and PTLD development may not only be related to the specificity of ATG vs ALG, but also potential differences in dose equivalency.
In summary, our results confirm and further expand upon previous observations of an increased risk of PTLD in pediatric BMT patients receiving T-cell-depleted grafts from mismatched related or matched unrelated donors. Our analyses indicate that in the setting of T-cell-depleted BMT, one must be cautious when considering in vivo anti-T-cell antibody therapy for additional GVHD prophylaxis. Use of ATG, relative to ALG, significantly increases the risk of PTLD, perhaps due to a more thorough and prolonged depletion of T cells and suppression of cellular immunity post BMT. Alternatively, ALG may have had some protective effect by more efficiently removing B cells from the circulation post BMT. Current strategies to remedy this problem might include utilization of pan lymphocyte depleting agents (ie Campath) post BMT for GVHD prophylaxis or, alternatively, to forgo use of in vivo T-cell-depleting antibody therapies in the setting of transplantation with ex vivo T-cell-depleted bone marrow or stem cell grafts. Investigations are currently needed to determine the optimal degree and specificity of TCD to minimize morbidity and mortality in alternative donor BMT.
